Business context and reporting period
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies RP1, RP2 and RP3. It has no approved products and has generated no product revenue. This unaudited Form 10-Q covers the three and six months ended September 30, 2022 (the second quarter and first half of fiscal 2023, for the fiscal year ending March 31, 2023).
Key financial metrics
Amounts below are in millions of dollars unless otherwise noted.
| Metric | Three months ended Sept. 30, 2022 | Three months ended Sept. 30, 2021 | Six months ended Sept. 30, 2022 | Six months ended Sept. 30, 2021 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $28.8 | $19.9 | $58.3 | $38.5 |
| Selling, general and administrative expense | $12.7 | $9.3 | $24.1 | $18.2 |
| Total operating expenses | $41.6 | $29.2 | $82.5 | $56.6 |
| Net loss | $43.1 | $29.4 | $85.4 | $56.7 |
| Net loss per share, basic and diluted | $0.79 | $0.56 | $1.57 | $1.09 |
| Cash used in operating activities | Not presented quarterly | $66.7 | $41.3 |
At September 30, 2022, cash and cash equivalents were $88.9 million and short-term investments were $282.9 million, totaling $371.8 million. Total assets were $436.1 million, total liabilities $52.0 million, and stockholders’ equity $384.1 million. Liabilities included $32.1 million of operating and finance lease liabilities; the filing reports no pre-October term-loan borrowing. Accumulated deficit was $396.6 million. The company recorded $1.1 million of investment income and $2.7 million of other expense in the quarter, the latter primarily reflecting foreign-exchange movements. No operating margin is meaningful because the company had no product revenue.
Material changes versus prior comparable periods
- Quarterly net loss increased $13.7 million year over year; first-half net loss increased $28.7 million.
- Quarterly R&D expense rose $8.9 million, reflecting increased RP1 trial activity, RP3 manufacturing development, personnel costs and lower Regeneron cost sharing. First-half R&D rose $19.9 million, including higher direct program spending and unallocated costs.
- Quarterly SG&A increased $3.4 million, including additional personnel and commercial planning costs; first-half SG&A increased $6.0 million.
- First-half operating cash use rose to $66.7 million from $41.3 million. Financing cash provided was $39.9 million, mainly from ATM share sales; the company reported $37.4 million of net ATM proceeds for the six-month period.
- Shares outstanding increased from 47.3 million at March 31 to 49.7 million at September 30. The company sold shares under its ATM programs and has a new ATM agreement allowing up to $100 million of additional sales.
Outlook, management commentary, risks and unusual items
- Management stated that, as of the filing, cash, cash equivalents and short-term investments, together with unrestricted proceeds available under the Hercules facility, were expected to fund operations into calendar 2025, including commercial infrastructure and a potential confirmatory trial. The estimate depends on assumptions and could prove inaccurate.
- On October 6, 2022, after quarter-end, Replimune entered a Hercules term-loan facility of up to $200 million. It drew an initial $30 million; another $30 million was available through September 30, 2023, with further tranches subject to milestones and/or lender approval. The facility has cash interest, 1.5% payment-in-kind interest, a 2027 maturity, an initial 48-month interest-only period and financial covenants.
- RP1 CERPASS, a 211-patient Phase 2 trial in cutaneous squamous cell carcinoma with cemiplimab, had completed enrollment; topline primary analysis was expected in the first half of 2023. A data snapshot from the first 75 patients in the IGNYTE anti-PD-1-failed melanoma cohort was expected in late 2022; the primary analysis was expected 12 months after final enrollment.
- Management expected RP2/RP3 program updates before year-end 2022 and planned to begin Phase 2 development work in the first half of 2023. These are expectations, not guarantees.
- Regeneron informed Replimune that reimbursement under the initial CERPASS study budget had ended. The parties were discussing cost sharing under a later budget; Replimune recorded no further reimbursement after that notice. Verify the status and recoverability of the reported $1.1 million receivable.
- The company’s Framingham manufacturing facility was operational; RP1 comparability work had been submitted to the FDA, while RP2 comparability studies were ongoing and RP3 manufacturing transfer was nearly complete. Manufacturing qualification, clinical trial execution and supply remain important risks.
- COVID-19 had affected or could affect trial enrollment, supplies and manufacturing. The filing also highlights clinical and regulatory uncertainty, reliance on third-party collaborators and suppliers, future financing needs, competition, and foreign-exchange exposure.
- On November 2, 2022, the company filed an inter partes review petition seeking to invalidate certain claims of Amgen U.S. Patent No. 10,034,938; the outcome and potential impact are uncertain. The company reported no material litigation and no material changes to internal financial controls during the quarter.
Important facts for investors to verify
- Whether clinical data and regulatory discussions support the anticipated RP1 filing pathway and stated trial timelines.
- Whether the reported runway into calendar 2025 remains supportable under updated cash burn, trial, manufacturing and commercialization plans.
- The actual amount and terms of Hercules borrowing, availability of later tranches, covenant compliance and associated interest and repayment obligations.
- Whether Regeneron confirms cost sharing under the revised CERPASS budget and whether the $1.1 million receivable is collected.
- Progress and regulatory acceptance of in-house manufacturing comparability and qualification for RP1, RP2 and RP3.
- Potential dilution from further ATM sales, equity compensation and other financing, and developments in the Amgen patent review.